Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Not Applicable
Recruiting
- Conditions
- Recurrent Meningioma
- Interventions
- Drug: Actinium Ac 225 DOTATATE RYZ101Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestRadiation: Gallium Ga 68-DOTATATEDrug: L-lysine/L-arginine-containing Amino AcidProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyProcedure: Somatostatin Receptor Positron Emission Tomography
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Joshua Palmer
- Target Recruit Count
- 30
- Registration Number
- NCT07150806
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Phase 1
Recruiting
- Conditions
- Lung CancerNSCLCBrain Metastases
- Interventions
- Radiation: Stereotactic Radiosurgery
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Joshua Palmer
- Target Recruit Count
- 56
- Registration Number
- NCT05987644
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
News
No news found